AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review

Go back to AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 56.86 +0.07 (0.12%)
Previous Close $56.79    52 Week High $35.04 
Open $57.69    52 Week Low $26.97 
Day High $57.69    P/E N/A 
Day Low $56.58    EPS $0.00 
Volume 6,493,338